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Abstract
The distinction between lymphatic and blood vessels is biologically fundamental. Here we wanted to rigorously
analyze the universal applicability of vascular markers and characteristics of the two widely used vascular model
systems human microvascular endothelial cell line-1 (HMEC-1) and telomerase-immortalized microvascular
endothelial cell line (TIME). Therefore we studied the protein expression and functional properties of the endothelial
cell lines HMEC-1 and TIME by flow cytometry and in vitro flow assays. We then performed microarray analyses of
the gene expression in these two cell lines and compared them to primary endothelial cells. Using bioinformatics we
then defined 39 new, more universal, endothelial-type specific markers from 47 primary endothelial microarray
datasets and validated them using immunohistochemistry with normal and pathological tissues. We surprisingly
found that both HMEC-1 and TIME are hybrid blood- and lymphatic cells. In addition, we discovered great
discrepancies in the previous identifications of blood- and lymphatic endothelium-specific genes. Hence we identified
and validated new, universally applicable vascular markers. Summarizing, the hybrid blood-lymphatic endothelial
phenotype of HMEC-1 and TIME is indicative of plasticity in the gene expression of immortalized endothelial cell
lines. Moreover, we identified new, stable, vessel-type specific markers for blood- and lymphatic endothelium, useful
for basic research and clinical diagnostics.
Citation: Keuschnigg J, Karinen S, Auvinen K, Irjala H, Mpindi J-P, et al. (2013) Plasticity of Blood- and Lymphatic Endothelial Cells and Marker
Identification. PLoS ONE 8(9): e74293. doi:10.1371/journal.pone.0074293
Editor: Nanette H Bishopric, University of Miami School of Medicine, United States of America
Received May 16, 2013; Accepted July 29, 2013; Published September 10, 2013
Copyright: © 2013 Keuschnigg et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Finnish Academy (grants 118621, 126925, 121584, 124282, 129378, 117787, and 41071), Juho Vainio
Foundation, Paavo Nurmi Foundation, Finnish Foundation of Cardiovascular Research and Finnish Cultural Foundation and Sigrid Juselius Foundation.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
* E-mail: marko.salmi@utu.fi
Introduction
Abnormal function of blood and lymphatic vessels is
important in multiple pathological conditions including
inflammation and cancer [1]. Many of these diseases involve
dysregulated formation of new vessels, and the endothelial
cells play a key role in this neo(lymph)angiogenic process.
Lymphatic endothelial cells (LECs) originally derive from
embryonic blood endothelial cells (BECs) during
embryogenesis. Therefore, it is not surprising that the two
endothelial cell types share features such as flat morphology,
apico-basal polarity and certain common endothelial-specific
proteins. However, many phenotypic and genetic
characteristics are unique for one or the other vessel type and
are routinely used to differentiate between blood and lymph
vessels in pathological specimens and vascular biology. For
instance, blood vessels express plasmalemma vesicle
associated protein 1 (PV-1), endoglin, neuropilin-1 (NRP-1)
and collagen IV [2]. Lymph vessels on the other hand express
markers such as podoplanin (PDPN), lymphatic endothelial
hyaluronan receptor-1 (LYVE-1), VEGF receptor-3 (VEGFR-3)
and prospero related homeobox 1 (PROX-1).
Many of these markers have been identified from microarray
studies in which differentially expressed BEC and LEC genes
have been analyzed from individual specimens. For instance,
microarray analysis of gene expression in cultured lymphatic
and blood dermal microvascular endothelial cells showed that
<400 genes are differentially expressed [3,4]. Among these
PROX-1 is known to be responsible for the induction of several
other LEC-specific genes and for the downregulation of
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numerous BEC-specific genes [4] making it the key regulator of
lymphatic cell differentiation [5].
Pathobiological processes involving endothelial cells, such
as inflammation, coagulation and neoangiogenesis, are often
studied in vitro. This requires the isolation and culture of BECs
and LECs. However, primary endothelial cells are difficult to
isolate (especially from humans) and cannot be cultured for
extended periods of time. Therefore, immortalized endothelial
cell lines are widely used as a substitute. These cells are
usually well characterized, express the accepted markers and
can be grown up to passage 40 and beyond. Two cell lines
extensively used as models for blood endothelial cells (more
than 800 citations in PubMed) are the polyoma-virus
transformed human dermal microvascular endothelial cell line-1
(HMEC‑1) [6] and the telomerase-immortalized human
microvascular endothelial cell line (TIME) [7]. They have been
reported by multiple morphological, phenotypical and functional
criteria to phenotypically and functionally represent BECs.
However, we unexpectedly noticed LEC-specific markers in
HMEC-1 and TIME. Therefore, we started to systematically
examine their hybrid phenotype at protein and gene expression
level. In addition, when comparing their gene expressions to
those of primary endothelial cells, the heterogeneity of BEC-
and LEC-specific gene expression profiles in different
published studies became apparent. Hence we generated a
novel, more universal database consisting of 47 primary blood-
and lymphatic endothelial gene expression profiles. We used
this tool to identify universally applicable new BEC and LEC
markers. We then showed the validity of this in silico approach
by testing two exemplary new markers in normal, chronically
inflamed and malignant tissues.
Materials and Methods
Cell isolation and culture
The original HMCE-1 cell line [6] was donated by Edwin W.
Ades from the Center for Disease Control and Prevention
(Atlanta, USA) and TIME cells [7] were purchased from ATCC
(#CRL-4025). Human umbilical vein endothelial cells
(HUVECs) were isolated and cultured as described [8].
Endothelial cells were cultured on plastic without coating.
Peripheral blood mononuclear cells (PBMC) and
polymorphonuclear cells (PMN) were isolated from healthy
donors using Ficoll-Paque Plus and Percoll gradient
centrifugation (Amersham Biosciences, Uppsala, Sweden).
Antibodies
The following primary antibodies were used: PAL-E [9]
(mIgG2a, Abcam, Cambridge, UK), anti-CD31 (mAb 2C8 [10],
mIgG1), anti-podoplanin (mIgG1, Acris Antibodies, Herford,
Germany), anti-LYVE-1 (rabbit IgG, Reliatech, Wolfenbüttel,
Germany). Anti-PV-1 antibody (174/2 [11], mIgG1), directly
labeled anti-PV‑1 (174/2-FITC [11,12]) and anti-Clever-1 (372
and 372-Alexa 488 [13], common lymphatic endothelial and
vascular endothelial receptor-1) were generated in our
laboratory. Goat polyclonal Abs against COLEC12 and MCAM
were from R&D Systems (R&D Systems, MN, USA).
As negative control antibodies we used AK-1 (mIgG1, In Vivo
Biotech Services GmbH, Hennigsdorf, Germany), mIgG2a neg.
contr. (R&D Systems), rabbit serum (C12SB, AbD Serotec,
Kindlington, UK) and goat serum (Vector Laboratories Inc.,
Burlingham, CA, USA).
Secondary antibodies were fluorophore-labeled (FITC, PE,
Alexa 488 and Alexa 546) anti-mouse IgG (total or isotype
specific), anti-rabbit IgG and anti-goat IgG (Sigma Aldrich,
Saint Louis, MO, USA and Molecular Probes, Eugene, OR,
USA).
Flow cytometry
Cells were fixed with 4% ice-cold paraformaldehyde and
permeabilized using a 0.02% saponin solution. The cells were
sequentially incubated with primary and secondary antibodies.
Appropriate isotype specific negative controls were used in all
stainings. Analyses were performed on a FACSCalibur System
using CellQuest Pro software (Becton Dickinson, Franclin
Lake, NJ, USA). Median fluorescence intensities of specific
stainings (sMFI) were calculated as [sMFI] = [MFI of the
antigen specific staining] - [MFI of corresponding negative
control].
Immunohistochemistry
All experiments involving human tissues were approved by
the Ethical Committee of the Hospital District of Southwest
Finland and written informed consent was obtained. The use of
tissues abided by the declaration of Helsinki. Frozen sections
of normal human peripheral lymph nodes, inflamed tonsils and
bladder cancer as well as colorectal cancer were incubated
with anti-COLEC12 and anti-MCAM antibodies followed by
incubation with Alexa Fluor 546-coupled second-stage
antibodies. In a third step we used directly labeled anti-PV-1
and anti-Clever-1 mAbs, which are established markers for
blood [11,14] and lymphatic vessels [13] as well as anti-
LYVE-1 and anti-podoplanin antibodies. Stainings were
mounted in ProLong Gold containing DAPI (Molecular Probes)
and analyzed on a LSM 510 confocal microscope using a Plan
Neofluar 20x/0,5 air objective and LSM ZEN software (Carl
Zeiss Microimaging, Göttingen, Germany).
Immunofluorescence
Cells were cultured on glass coverslips (Menzel,
Braunschweig, Germany) in 24-well plates. Cells were fixed in
0.2% paraformaldehyde and permeabilized with 0.2% Triton
X-100 in PBS for 5 min on ice. After sequential incubation with
primary and secondary antibodies cells were mounted as
above and analyzed on a LSM 510 confocal microscope using
a Plan Neofluar 40x/1.3 Oil-immersion objective and LSM ZEN
software.
In vitro flow assay
The protocol was modified from [15]. HMEC-1, TIME and
HUVECs were seeded at 1.25 x 105 cells per channel into ibidi
μ-slide VI 0,4 chambers (ibidi GmBH, Martinsried, Germany)
coated with ibiTreat and grown to confluence overnight. In the
morning, medium was replaced with fresh medium containing
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100 U TNF-α ml-1 (for rolling and adhesion experiments) or
500 U TNF-α ml-1 (for transmigration experiments).
At the beginning of the experiment the channel was
stabilized for one minute with binding buffer (Dulbecco’s
Phosphate Buffered Saline containing 0.1% human serum
albumin) using a laminar shear of 0.75 dyn cm-2. PBMCs or
PMNs (1 x 106 cells ml-1 in binding buffer) were then perfused
through the capillary at 0.75 dyn cm-2. Rolling and adherent
cells were analyzed two minutes after addition of PBMCs or
PMNs to the capillary by recording 5 fields (0.5676 mm2 per
field) for 15 s each.
For interaction and transmigration studies, PBMCs or PMNs
(1 x 106 cells ml-1 in binding buffer) were perfused through the
capillary for 5 min at 0.75 dyn cm-2 followed by binding buffer
(without cells) for 10 min for PMN and 20 min for PBMC at the
same laminar shear to allow adherent cells to transmigrate.
Interaction and transmigration of PMN were analyzed by
recording 5 fields 10 min after perfusion of cells, and for
PBMCs the same analyses were done at 20 min after
perfusion. Assays were performed with an Olympus IX70
inverted microscope (Olympus, Tokyo, Japan) equipped with a
cooled ORCA-R2 CCD camera (Hamamatsu, Hamamatsu City,
Japan) using 100x magnification. For each experiment (n=3)
different HUVECs as positive control and PBMCs/PMNs
isolated from different healthy donors were used.
Analyses were carried out off-line by manual counting. 5
fields per capillary were analyzed for rolling, adherent and
transmigrated cells. Cells were defined as rolling if they moved
slowly into the direction of flow and as adherent if they
remained stationary. At later time points, phase bright cells
were counted as adherent and phase dark cells as
transmigrated underneath the endothelium. The percentage of
transmigrating cells was calculated as [migrating cells]/
([adherent cells] + [migrating cells]). The absolute numbers of
counted PMN with HUVECs (positive control) per experiment
were: 19 ± 3 (mean ± s.e.m.) rolling and 827 ± 24 adherent
cells (2 min time point); 1471 ± 206 adherent and 149 ± 34
transmigrated cells (10 min time point). In case of PBMC, 38 ±
3 cells rolled and 323 ± 43 adhered after 2 minutes, and 480 ±
55 cells adhered and 54 ± 13 cells transmigrated at the 20 min
time point.
HMEC-1 and TIME microarray
We tested the effect of the confluency of the cell cultures on
the gene expression and found some differences (data not
shown). Therefore we standardized our cell cultures and used
80% confluent cultures for our experiments. Total RNA was
isolated from ~80% confluent HMEC-1 and TIME cultures using
a NucleoSpin RNA isolation kit (Macherey & Nagel, Düren,
Germany). Samples were subsequently processed with
Affymetrix GeneChip 3’ IVT Express Kit and hybridized to
GeneChip Human Genome U133 plus 2.0 Array (all Affymetrix,
Santa Clara, CA, USA) at +45°C. All assay steps were
performed independently with four biological replicates of each
cell type. Samples are deposited in Geo Datasets with the
accession number GSE42216.




BEC and LEC gene expression datasets
To analyze differential gene expression between BECs and
LECs, 47 publicly available gene expression profiles from the
Gene Expression Omnibus (GEO) database [16] were used.
The datasets were derived from three different Affymetrix gene
expression platforms: Human Genome U133 Plus 2.0 Array
(GPL570), Human Genome U133A 2.0 Array (GPL571) and
Human Exon 1.0 ST Array (GPL5188). Distribution of samples
and cell types over the platforms and grouping into Datasets A
and B is shown in Table S1 in File S1. A complete list of the
samples including their annotations is available as Table S2 in
File S1.
The raw gene expression data for each sample was
downloaded from the GEO database [16]. The probes were
annotated for their gene identifications from the Ensembl
database [17] using a custom probe mapping [18]. The
samples from each of the three platforms (GPL570, GPL571,
GPL5188) were normalized in subgroups using GC-RMA [19]
and their expression values log2-transformed. Subsequently,
the three datasets representing different gene array versions
were combined into a complete expression matrix using the
reannotated gene identifications. Genes that did not have
expression values in at least 40% of the samples were
removed, after which our datasets contained 19081 genes. To
account for inter-platform differences we subtracted each
gene’s median expression from the gene’s expression values
and divided the result with the gene’s standard deviation. This
was done for the complete expression matrix that contained all
samples from all platforms. The complete expression matrix
can be downloaded from http://users.utu.fi/masalmi/
Keuschnigg_Suppl_Dataset_I.xlsx.
A multidimensional scaling (MDS) plot (Euclidean distance)
was created for Dataset A, HMEC-1, TIME and prostate control
samples, which were normalized using GC‑RMA [19]. For
ingenuity IPA-software analysis genes that met the cut-off of
≥2-fold change in expression with a multiple hypotheses
corrected p-value of ≤0,05 and that were associated with
biological functions in the Ingenuity Knowledge Base were
considered for the analysis.
Statistical analyses
Results of the in vitro flow experiments are expressed as
means ± standard error of mean. Two-tailed student’s t-test
with unequal variance was used to evaluate statistical
significance. For the microarray analysis p-values were multiple
hypotheses corrected using robust false discovery rate
estimation [20]. Genes that were differentially expressed with
multiple hypotheses corrected p-value ≤ 0.05 and fold change
≥ 2 were considered as significant. For ingenuity IPA analyses,
right-tailed Fisher’s exact test was used to calculate the p-
values.
Plasticity in Endothelial Cell Gene Expression
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Results
HMEC-1 and TIME express both lymphatic and blood
vascular markers
We searched for suitable immortalized endothelial cell lines
to be used in inflammation models for human blood vascular
endothelium. Based on a plethora of literature we focused on
HMEC-1 and TIME cells. Flow cytometric analyses indeed
confirmed the expression of established BEC markers PAL-E
and CD31 on both cell types (Figure 1A). Both, the anti-PV-1
antibody and PAL-E recognize PV-1, albeit different epitopes
[11,12]. The shift of the entire peak when compared to the
negative control indicates low-level expression of PV-1 in all
cells. Strikingly, however, both HMEC-1 and TIME were also
uniformly positive for the lymphatic marker PDPN. In addition,
both cell lines also expressed CLEVER-1 and low levels of
LYVE-1 (Figure 1B). To confirm the expression of both types of
markers in the same cell, we stained TIME cells for microscopy
(Figure 1C). Indeed we could show that PV-1 and CD31 are
expressed in the same cell as PDPN. Thus, HMEC-1 and TIME
cells express a mixture of both vascular and lymphatic cell
markers and are therefore clearly distinct from blood
endothelial cells.
Altered leukocyte-endothelial adhesion cascade in
HMEC-1 and TIME cells
To study how HMEC-1 and TIME behave in functional
assays we analyzed leukocyte-endothelial cell interactions in
an in vitro flow assay. PBMC rolling and adhesion on both
HMEC-1 and TIME were severely impaired when compared to
freshly isolated HUVECs (Figure 2A). Similarly, the absolute
numbers of interacting PBMC (firmly adhering and
transmigrating) were significantly decreased by ~60% on both
HMEC-1 and TIME (Figure 2B).
Extravasation of PMN across TIME monolayers occurred
with similar efficiency as on HUVECs. On the other hand, both
rolling and adhesion of PMN on HMEC‑1 were significantly
impaired (Figure 2A). Furthermore, the absolute numbers of
PMN interacting with HMEC-1 were significantly decreased by
>50% (Figure 2B).
However, once firmly adhered, comparable percentages of
PBMC and PMN transmigrated across HUVEC, HMEC-1 and
TIME monolayers. Thus, HMEC-1 and TIME cells differ from
pure endothelial HUVECs in their capacity to support several
steps of leukocyte extravasation.
Genome wide expression profiling of HMEC-1 and TIME
places them near to BECs and LECs
To get a more global view on the phenotypic alterations in
HMEC-1 and TIME, gene expression analyses were
performed. We subjected resting HMEC-1 and TIME cells to
Affymetrix microarray analyses and compared the results to
BEC- and LEC microarray data available in the public domain
(Geo DataSets [16]). For that purpose we combined 14 BEC
and 10 LEC datasets from the same platform as our own
HMEC-1 and TIME analysis (GPL570) to produce Dataset A.
MDS is a visualization methodology that aims at finding
similarities between data points [21]. Here the 3D-MDS plot
clusters biological samples according to their genome-wide
expression profiles. Prostate tissue was included for an
unbiased comparison of distances between HMEC-1, TIME,
BEC and LEC samples. As illustrated in Figure 3A and the
Movie S1, TIME and HMEC‑1 cluster near to, but not among
primary endothelial cells. They appear to be somewhat more
closely related to BECs than to LECs. Moreover, the
expression of several genes was up- or down-regulated in
HMEC-1 and TIME in comparison to primary BEC and LEC
(Figure 3B) in the normalized Dataset A. There were also
notable differences in the expression of some genes (such as
complement factor H, adenylate kinase 5 and SAM domain,
SH3 domain and nuclear localizations signals 1), between
HMEC-1 and TIME. Thus, also the gene expression patterns in
HMEC-1 and TIME are clearly different from those of pure
BECs.
Search for new BEC/LEC markers using publicly
available microarray data
As microarray analyses often rely on cells freshly isolated
from one or a few individuals, one drawback of these analyses
is usually the limited biological variability. We therefore
hypothesized that analyses of numerous pooled BEC- and LEC
microarray datasets could result in the discovery of previously
unknown, differentially expressed genes and thus more
universally applicable BEC/LEC markers. Even though
combining datasets from different parts of the vascular tree
[22,23] results in the loss of vascular bed-specific information, it
is the only way to increase the possibility to find true BEC/LEC
specific markers when analyzing dozens of microarrays
created by several laboratories.
We used our Dataset A (14 BEC and 10 LEC from the same
platform) for the initial comparisons. In addition, we queried the
NCBI GEO DataSets [16] database and assembled a larger
dataset of 33 BEC and 14 LEC (Dataset B). These 47
microarray experiments with primary cells come from 12
separate experiments run on three different Affymetrix
platforms. In addition we compared our results with two
previously published studies, which have specifically aimed at
reporting differently expressed genes in BEC and LEC [3,4].
Comparison of the smaller Dataset A with the extensive
Dataset B exhibits only a limited overlap, when using a
threshold of ≥2-fold change in expression levels with a multiple
hypotheses corrected p-value of ≤0,05 to define a differentially
expressed gene. For BEC-specific molecules, Dataset A
revealed 27 and Dataset B 28 genes with 15 genes being
common to both analyses. For LEC-specific molecules, 13
were identified from Dataset A, 28 from Dataset B, with 10
genes being LEC-specific in both datasets (Figure 4A).
Comparison of our analysis of Dataset B to previous
analyses performed by Hirakawa et al [3] and Petrova et al [4]
also revealed very little overlap (Figure 4B). In BECs only two
and in LECs three genes were common to all three studies. All
three analyses found the prototype LEC markers podoplanin
and PROX-1 to be specific for LECs. The third LEC-specific
protein was reelin [24] (RELN). In contrast, none of the
commonly used BEC markers was scored as BEC-specific in
all three studies. Surprisingly, both genes consistently found to
Plasticity in Endothelial Cell Gene Expression
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be BEC-specific were neuronal cell adhesion molecule [25]
(NRCAM) and chemokine ligand 1 [26] (CXCL1; Table 1, Table
S3 in File S1).
Further analysis of the results using IPA software (Ingenuity®
Systems, www.ingenuity.com) showed that both LEC and BEC
specific genes were mostly involved in processes such as
cardiovascular system development, tissue development and
organ development (p-values ranging from ≤0,05 to ≤0,0001),
supporting their potential relevance to cell differentiation.
Two new markers MCAM and COLEC12 are useful for
the distinction between blood and lymphatic
Figure 1.  HMEC-1 and TIME express both blood vascular and lymphatic markers.  HMEC-1 and TIME cells were stained for
flow cytometry using the indicated antibodies against (A) blood vascular markers and (B) lymphatic markers. The marker region
shows the antigen-specific staining and is set based on the species- and isotype-specific negative controls. One representative
negative control is depicted here. The numbers in the upper right corners of the histograms are the specific median fluorescence
intensities of the given antigen, calculated as detailed in materials and methods. (C) Representative images of TIME cells
simultaneously expressing lymphatic and blood vascular markers in the same cell are depicted and indicated with white arrows. The
scale bar represents 20 µm.
doi: 10.1371/journal.pone.0074293.g001
Plasticity in Endothelial Cell Gene Expression
PLOS ONE | www.plosone.org 5 September 2013 | Volume 8 | Issue 9 | e74293
Figure 2.  HMEC-1 and TIME show aberrant leukocyte-endothelial interactions under physiological shear stress.  (A) Rolling
and adhesion of PBMC and PMN on HMEC-1, TIME and HUVEC were analyzed using in vitro flow assay. The results are
normalized to HUVEC (100%). (B) Absolute numbers of interacting (firmly adhering and transmigrating) leukocytes and (C) the
transmigration percentage (the numbers of transmigrated cells divided by the numbers of interacting cells) on the three endothelial
monolayers were determined. Data are shown as mean ± SEM (n = 3 for each assay, each with different leukocyte donors). *P ≤
0.05. **P ≤ 0.01. ***P ≤ 0.001. (D) Images of representative endothelial monolayers 10 min. after start of PMN transmigration
studies are shown. Phase contrast bright cells (representative cells indicated by white arrows) are located on the apical surface of
the endothelial cells and phase contrast dark cells (representative cells indicated by white arrow-heads) are situated below the
monolayer. Note that all three endothelial types form confluent intact monolayers. Inserts show adhering and transmigrating cells in
more detail. Scale bars represent 100 µm.
doi: 10.1371/journal.pone.0074293.g002
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Figure 3.  Gene expression profiles of HMEC-1 and TIME reveal differences from pure BEC and LEC.  (A) A multidimensional
scaling plot (MDS-plot) showing clustering of TIME, HMEC-1, primary BEC and LEC (and prostate tissue as a control) based on the
expression of about 19000 genes. (B) Exemplary genes that are differently expressed in HMEC-1 and/or TIME when compared to
BEC and LEC in the normalized Dataset A. Data is presented as mean with the middle quartile and minimum/maximum values.
doi: 10.1371/journal.pone.0074293.g003
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endothelium in normal, chronically inflamed and
cancerous tissues
Using the list of new blood- and lymphatic endothelium
specific molecules derived from analyses of Dataset B we
chose the proteins melanoma cell adhesion molecule (MCAM)
as a new BEC-marker and collectin placenta 12 (COLEC12) as
LEC-marker to test whether our in silico findings could also be
confirmed in an independent manner. To that end we examined
how the new markers relate to the established vascular marker
PV-1 [12] and lymphatic markers CLEVER-1 [13] (common
lymphatic endothelial and vascular endothelial receptor-1),
LYVE-1 and podoplanin in immunohistochemical stainings
(Figure 5). The new BEC marker MCAM colocalized very well
with the established blood vascular marker PV-1 (the epitope of
the widely used antibody PAL-E; pathologische anatomie
leiden-endothelium [12]), while there was no overlap with the
staining pattern of the LEC markers CLEVER-1 and
podoplanin. Similarly, the new LEC marker COLEC12 showed
the expected staining pattern with colocalization with
CLEVER-1 and LYVE-1 and mutually exclusive staining with
PV-1. Thus, our new in silico derived list of BEC- and LEC
specific genes should be useful for identification of new
markers with a wide application range.
Figure 4.  Identification of BEC and LEC specific genes in different individual- and pooled microarray analyses.  (A) The
numbers of BEC and LEC specific genes obtained from analyses of a restricted Dataset A (24 samples, one platform: GPL570) and
of an extensive Dataset B (47 samples, three platforms: GPL570, GPL571 and GPL5188) are shown using Venn-diagrams. (B)
Similar comparisons were performed between our extensive Dataset B and two individual studies (Hirakawa and Petrova) reporting
BEC- and LEC specific genes.
doi: 10.1371/journal.pone.0074293.g004
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Table 1. BEC- or LEC-specific genes in different microarray studies.
Blood endothelial cell specific genes
Intersection: Keuschnigg Keuschnigg Keuschnigg Petrova Keuschnigg Petrova Hirakawa
 Petrova Petrova Hirakawa Hirakawa    
 Hirakawa       
Number of genes: 2 7 0 19 19 127 34
Genes: NRCAM TAGLN  CD44 FSTL1 IL8 AUTS2
 CXCL1 RNASE1  LTBP2 MCAM AXL DSG1
  CAP2  ITGA5 ZNF207 FAP ITGA4
  PLA2G4A  BMP6 VAMP8 ACTA2 GPR39
  ISG15  VCAN RGS5 KRT7 COL6A3
  DKK1  CXCR4 SEC 61B LPHN2 IL13RA2
  IFI27  SRGN GLIPR1 SELP FBLN5
    IL4R SH3BP4 TPM2 BMP1
    FLT1 EMP3 SERPINE1 CSF2RB
    PCDH1 TSPAN3 IGF2BP3 ITGB3
    VEGFC HOXB2 PLAU VWF
    CDH2 JAM3 PFN2 F2R
    COL1A2 NCL CHST1 ESM1
    PGF RP3-523C21.1 MMP1 EFEMP2
    CCL2 CCT5 BASP1 CD93
    C17orf72,ICAM2 SHISA3 MLLT11 SPARC
    ITGB5 MCTP1 CLU LAMC1, LAMB2
    CCRL2 GATA6 TGFBI PECAM1
    COL6A1 C1orf54 IL6 FN 1
      TRIM22 LAMB1
      * *
Lymphatic endothelial cell specific genes
Intersection: Keuschnigg Keuschnigg Keuschnigg Petrova Keuschnigg Petrova Hirakawa
 Petrova Petrova Hirakawa Hirakawa    
 Hirakawa       
Number of genes: 3 4 1 6 20 106 15
Genes: PROX1 GMFG CEACAM1 CXCL12 PVRL3 RBP1 F2RL1
 PDPN FABP4  MRC1,MRC1L1 TNFSF10 MAF LGALS8
 RELN PPARG  CALCRL HSD17B2 CH25H PSMG1
  MGP  TFF3 CD36 SEPP1 CCL5
    ANGPT2 ID1 SLC26A4 JUP
    DSP,SNRNP48 ADRB1 RGS16 GLRB
     NID1 ITGA9 THBS1
     LAYN CDKN1C HMMR
     ADAMTSL3 CRMP1 IL6ST
     SNAI2 PCSK6 JAG1
     EPS8 ITGA1 CCL20
     AK5 MEF2C TGFA
     RP11-65D13.1 APOD FGF12
     FDFT1 PDLIM3 ITGA6
     GRAMD3 CCNE2 MFAP3
     COLEC12 TIMP3  
     GHR CD200  
     HEY1 ADD3  
     GYPC TK1  
     TFPI LIPA  
      *  
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Discussion
Based on protein expression, gene expression and functional
analyses this study shows that the two widely used endothelial
cell lines HMEC-1 and TIME exhibit a hybrid phenotype
different from pure blood vascular or lymphatic endothelial
cells. Furthermore, combination of a comprehensive set of
publicly available microarray datasets from primary endothelial
cells allowed us to identify novel BEC and LEC markers. This
in silico approach was feasible for discovery of novel cell-type
specific molecules since two representative candidates were
successfully validated in independent biological
experimentation using normal, inflamed and malignant tissues.
HMEC-1 and TIME are two notable examples of
immortalized blood vascular models that have been widely
used (their original publications have been cited over 800
times). Both were generated from dermal microvascular
endothelial cells without apparent selection for blood vascular
Table 1 (continued).
Results from the individual studies are marked by the name of the first authors. The terms “intersection” and “number of genes” refer to the overlaps between the individual
studies in the venn diagrams in Figure 4B.
* Indicates truncation of gene list after the top 20 genes. For a complete list see Table S3 in File S1.
doi: 10.1371/journal.pone.0074293.t001
Figure 5.  MCAM and COLEC12 are novel BEC- and LEC- specific markers.  Two new endothelial markers MCAM and
COLEC12 (selected from our analysis of Dataset B) were used to stain (A) normal human lymph nodes together with two
established vascular markers PV-1 (for BEC) and CLEVER-1 (for LEC). In addition, (B) chronically inflamed tonsils and (C)
specimens from bladder cancer and colorectal cancer were stained with the antibodies against the indicated proteins. LYVE-1 and
COLEC12 co-staining was done on colorectal cancer specimens, whereas the other stainings represent bladder cancer. MCAM
staining colocalized very well with the established BEC marker PV-1 whereas no colocalization could be detected between MCAM
and the established LEC markers LYVE-1 and podoplanin. COLEC12-staining on the other hand showed colocalization with LYVE-1
but not PV-1. White arrows point to areas of colocalization. Nuclear counterstaining was performed with DAPI. Scale bars represent
100 µm.
doi: 10.1371/journal.pone.0074293.g005
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endothelial cells [6,7]. As the human microvasculature consists
of both BECs and LECs, immortalization without enrichment for
one cell type could create a mixed cell line with two different
cell populations. Nevertheless, our analyses unambiguously
showed that both HMEC-1 and TIME only contain one
homogenous population simultaneously expressing markers for
both BECs and LECs. During vascular development, both
BEC- and LEC markers are transiently present in the same cell
and recently it was discovered that LECS also express the
blood endothelial fate regulators chicken ovalbumin upstream
transcription factor and NOTCH [27]. These findings suggest a
delicate balance where minor variations in the expression of
the cell fate regulators cause major changes in the endothelial
cell differentiation.
Immortalization of primary endothelial cells causes a
significant change in their gene expression profile [28].
Furthermore, it can cause changes in the functional properties
such as response to cytokines and migration of peripheral
blood mononuclear cells across endothelial cells [29].
Interestingly, not only artificially manipulated cells can exhibit
modified phenotypes and genotypes, as primary HUVECs for
example have been shown to adopt a lymphatic-like phenotype
in in vitro angiogenesis assays [30]. Previous studies have also
demonstrated a loss of lineage specific markers in tissue
culture [31] and the importance of extracellular matrix
environment for maintaining the cell identity [32]. This well-
established plasticity of blood- and lymphatic endothelial cells
might explain why HMEC-1 and TIME exhibit a mixed
phenotype.
Both HMEC-1 and TIME showed abnormal interactions with
leukocytes in functional assays. This is in line with a previous
report demonstrating impaired induction of adhesion molecules
on HMEC-1 and TIME as well as absence of rolling. However,
the endothelial monolayers used in these experiments
appeared to be subconfluent [33]. With our confluent
monolayers (Figure 2D) we clearly showed that rolling, firm
adhesion and transmigration of both lymphocytes and
granulocytes do take place with HMEC-1 and TIME, albeit
there were quantitative differences in comparison to pure BEC.
However, these abnormalities seem to be restricted to early
events during the leukocyte extravasation cascade (namely
rolling and adhesion). Once leukocytes firmly adhered, the
percentages of cells that also transmigrated across the
endothelium were comparable between HUVECs, HMEC-1 and
TIME. Aberrations in adhesion molecule expression and
functions of HMEC-1 and TIME have been first mentioned
already in 2004 [34] and 2007 [33]. Surprisingly, these cells
have remained widely used models for blood vasculature
[35,36]. Our comprehensive characterization of both HMEC-1
and TIME now clearly indicates that they are poorly suited as
BEC models.
In our analyses we used HUVECs, a widely used model
system [37–40] for the comparison of leukocyte transmigration.
These cells are embryonic macrovascular endothelial cells and
exhibit only limited similarity with adult microvascular
endothelial cells, the cell type across which most of the
leukocyte transmigration occurs. As microvascular endothelial
cells facilitate the majority of leukocyte transmigration, our
results using macrovascular endothelial cells as a reference
material might actually underestimate the impaired capacity for
leukocyte transmigration exhibited by the microvascular
endothelial cell lines HMEC-1 and TIME. However, once
activated, HUVECs do allow leukocytes to adhere and
transmigrate with similar efficiency as adult dermal
microvascular endothelial cells do [33].
As stainings and in vitro flow assays concentrate only on a
limited number of proteins, we performed microarray analyses
to investigate the genome wide expression profiles of HMEC-1
and TIME and compared them to those of primary BECs and
LECs. In global expression profiling (MDS-plots), TIME and
HMEC-1 cluster distantly from each other, but both endothelial
cell lines seem to be relatively closely related to normal BECs.
However, this clustering is based on the expression of ≥19000
genes. Considering the fact that only a minor fraction of these
genes (<400) seems to be differentially expressed between
BEC and LEC [3,4], this result is expected and likely represents
an overestimation of the relatedness. Indeed, when analyzing
individual genes, it was obvious that both HMEC-1 and TIME
express several genes not typically found in endothelial cells.
These findings once more demonstrate the differences
between immortalized endothelial cell lines and primary cells.
In addition, in vitro systems can never fully reproduce the
situations predominant in living organisms. Taken together,
these points emphasize the need for validation of data using
primary endothelial cells and in vivo models.
While analyzing the gene expression profiles of primary BEC
and LEC in the literature, it became apparent that there is
surprisingly little overlap between individual published analyses
of BEC- and LEC-specific gene expressions. Hence we utilized
our pooled microarray dataset for the identification of novel,
universal BEC- and LEC-specific gene expression profiles from
primary endothelial cells. Biological sample heterogeneity and
differences in cell isolation protocols and preprocessing may
account for some variability. For instance, to isolate LECs,
Hirakawa et al. [3] used the criteria of CD34-, CD31+, while
Petrova et al. [4] used CD31-, PDPN+ cells. Furthermore, the
threshold for genes to be considered as BEC/LEC specific was
set as increase in gene expression with p≤0,002 in the first
publication and as 2-fold change in expression levels in the
second study. Despite their different analysis criteria, both
groups report <400 genes to have changed at least 2-fold
between BECs and LECs.
Introduction of biological variability clearly affects the results,
since in our analyses the 40% increase in the sample size in
Dataset B resulted in the doubling of genes found to be specific
for LECs. However, most of the genes present in the restricted
Dataset A were also present in the extensive sample set B.
This most probably reflects the rather homogenous nature of
LECs. In any case, it is noteworthy that none of the commonly
accepted BEC markers (e.g. PV-1, endoglin, FVIII) were
common to all three analyses. Thus, great caution should be
exercised when alluding to the discovery of global cell-type
specific markers using low numbers of biological samples.
While the identification of the prototype LEC markers
PROX-1 and podoplanin strongly supports our results, the
other common genes, RELN, NRCAM and CXCL1 are not
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usually used for discrimination between BEC and LEC. RELN
was found to play a role in radial migration of cortical neurons
and maturation of dendrites and was shown to be involved in
NOTCH-signaling [41]. The importance of NOTCH-signaling for
BEC/LEC specialization could explain the finding of RELN as
LEC marker. NRCAM is a neuronal cell adhesion molecule and
during neural development it is for example involved in cell
proliferation, differentiation and axon growth and guidance
(reviewed in [42]). NRCAM has been shown to interact with
laminin [43], a protein found to be BEC specific [3].
Interestingly, NRCAM has also been found to associate with
neuropilin-2 [44], the co-receptor of the LEC marker VEGFR-3
[2]. CXCL1 on the other hand was recently shown to be
induced by prostaglandin E2 and to function in angiogenesis by
stimulating microvascular endothelial cell migration and tube-
formation [45]. Thus, as is the case with established LEC and
BEC markers, none of the new markers is endothelium specific
[46–49], but among endothelial subtypes they selectively seem
to be expressed either on BEC or LEC.
We confirmed the specificity of representative novel markers
with biological samples. MCAM and COLEC12 showed very
strong colocalization with the established BEC and LEC
markers in immunohistological stainings of human lymph nodes
(Figure 5A), chronically inflamed tonsils (Figure 5B) and
malignant tissues (Figure 5C). Notably, neither of them was
identified by Hirakawa et al. [3] or Petrova et al [4] as
endothelium-subtype specific molecules. Nevertheless, it
should be noted that MCAM has been previously found to be
expressed on haematopoietic cells [50] and tumor cells [51],
where it plays a role in the interaction with vascular endothelial
cells. In addition, MCAM expression has also been identified on
endothelial cells [52,53]. However, its usefulness for the
distinction between vessels of blood- and lymphatic origin is
new and currently MCAM is not commonly used as endothelial
marker.
In conclusion, we demonstrate that the widely used
endothelial cell lines HMEC-1 and TIME are not
representatives of microvascular blood vascular phenotype, but
instead are hybrid cells with both vascular and lymphatic
characteristics. Furthermore we show that BEC- and LEC
specific gene expression profiles in primary cells differ greatly
between individual analyses and that it is possible to identify
new universally applicable BEC and LEC-specific molecules
through analyses of pooled microarray data.
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Movie S1.  3D MDS plot of BEC, LEC, HMEC-1 and TIME
clustering. A 3-dimensional animation of the clustering of
BEC, LEC, HMEC-1 and TIME samples according to their
genome wide gene expression. Prostate tissue allows an
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